Abstract
An area of therapeutic interest in cancer biology and treatment is targeting the cancer stem cell, more appropriately referred to as the cancer initiating cell (CIC). CICs comprise a subset of hierarchically organized, rare cancer cells with the ability to initiate cancer in xenografts in genetically modified murine models. CICs are thought to be responsible for tumor onset, self-renewal/maintenance, mutation accumulation and metastasis. CICs may lay dormant after various cancer therapies which eliminate the more rapidly proliferating bulk cancer (BC) mass. However, CICs may remerge after therapy is discontinued as they may represent cells which were either intrinsically resistant to the original therapeutic approach or they have acquired mutations which confer resistance to the primary therapy. In experimental mouse tumor transplant models, CICs have the ability to transfer the tumor to immunocompromised mice very efficiently while the BCs are not able to do so as effectively. Often CICs display increased expression of proteins involved in drug resistance and hence they are intrinsically resistant to many chemotherapeutic approaches. Furthermore, the CICs may be in a suspended state of proliferation and not sensitive to common chemotherapeutic and radiological approaches often employed to eliminate the rapidly proliferating BCs. Promising therapeutic approaches include the targeting of certain signal transduction pathways (e.g., RAC, WNT, PI3K, PML) with small molecule inhibitors or targeting specific cell-surface molecules (e.g., CD44), with effective cytotoxic antibodies. The existence of CICs could explain the high frequency of relapse and resistance to many currently used cancer therapies. New approaches should be developed to effectively target the CIC which could vastly improve cancer therapies and outcomes. This review will discuss recent concepts of targeting CICs in certain leukemia models
Keywords: Therapeutic sensitivity, targeted therapy, PI3K, PTEN, Akt, mTOR, radiological, xenografts, chemotherapeutic, germinal mutation
Current Pharmaceutical Design
Title:Targeting the Cancer Initiating Cell: The Ultimate Target for Cancer Therapy
Volume: 18 Issue: 13
Author(s): James A. McCubrey, Linda S. Steelman, Stephen L. Abrams, Negin Misaghian, William H. Chappell, Jorg Basecke, Ferdinando Nicoletti, Massimo Libra, Giovanni Ligresti, Francac Stivala, Danijela Maksimovic-Ivanic, Sanja Mijatovic, Giuseppeo Montalto, Melchiorre Cervello, Piotr Laidler, Antonio Bonati, Camilla Evangelisti, Lucio Cocco and Alberto M. Martelli
Affiliation:
Keywords: Therapeutic sensitivity, targeted therapy, PI3K, PTEN, Akt, mTOR, radiological, xenografts, chemotherapeutic, germinal mutation
Abstract: An area of therapeutic interest in cancer biology and treatment is targeting the cancer stem cell, more appropriately referred to as the cancer initiating cell (CIC). CICs comprise a subset of hierarchically organized, rare cancer cells with the ability to initiate cancer in xenografts in genetically modified murine models. CICs are thought to be responsible for tumor onset, self-renewal/maintenance, mutation accumulation and metastasis. CICs may lay dormant after various cancer therapies which eliminate the more rapidly proliferating bulk cancer (BC) mass. However, CICs may remerge after therapy is discontinued as they may represent cells which were either intrinsically resistant to the original therapeutic approach or they have acquired mutations which confer resistance to the primary therapy. In experimental mouse tumor transplant models, CICs have the ability to transfer the tumor to immunocompromised mice very efficiently while the BCs are not able to do so as effectively. Often CICs display increased expression of proteins involved in drug resistance and hence they are intrinsically resistant to many chemotherapeutic approaches. Furthermore, the CICs may be in a suspended state of proliferation and not sensitive to common chemotherapeutic and radiological approaches often employed to eliminate the rapidly proliferating BCs. Promising therapeutic approaches include the targeting of certain signal transduction pathways (e.g., RAC, WNT, PI3K, PML) with small molecule inhibitors or targeting specific cell-surface molecules (e.g., CD44), with effective cytotoxic antibodies. The existence of CICs could explain the high frequency of relapse and resistance to many currently used cancer therapies. New approaches should be developed to effectively target the CIC which could vastly improve cancer therapies and outcomes. This review will discuss recent concepts of targeting CICs in certain leukemia models
Export Options
About this article
Cite this article as:
James A. McCubrey, Linda S. Steelman, Stephen L. Abrams, Negin Misaghian, William H. Chappell , Jorg Basecke, Ferdinando Nicoletti, Massimo Libra, Giovanni Ligresti, Francac Stivala, Danijela Maksimovic-Ivanic , Sanja Mijatovic, Giuseppeo Montalto, Melchiorre Cervello, Piotr Laidler, Antonio Bonati, Camilla Evangelisti, Lucio Cocco and Alberto M. Martelli , Targeting the Cancer Initiating Cell: The Ultimate Target for Cancer Therapy , Current Pharmaceutical Design 2012; 18 (13) . https://dx.doi.org/10.2174/138161212799859701
DOI https://dx.doi.org/10.2174/138161212799859701 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: New Advances of Drug Design in Cancer Disease Part I)
Current Bioactive Compounds The Blood-Brain Barrier: Its Influence in the Treatment of Brain Tumors Metastases
Current Cancer Drug Targets Generation of Targeted Adeno-Associated Virus (AAV) Vectors for Human Gene Therapy
Current Pharmaceutical Design DMBA- Induced Breast Cancer: A Hormonal Camouflage
Current Cancer Therapy Reviews Hapten Recognition by T Cells: A Functional and Molecular View
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Bioplex Technology: Novel Synthetic Gene Delivery Pharmaceutical Based on Peptides Anchored to Nucleic Acids
Current Pharmaceutical Design The Dilemma of Localizing Disease Relapse After Radical Treatment for Prostate Cancer: Which is the Value of the Actual Imaging Techniques?
Current Radiopharmaceuticals “Good Fashion is Evolution, Not Revolution” - Methods to Enhance Existing Anticancer Medicines, Primarily with the Use of Transition Metal
Anti-Cancer Agents in Medicinal Chemistry WNT Signaling in Stem Cell Biology and Regenerative Medicine
Current Drug Targets Nuclear Proteins: Promising Targets for Cancer Drugs
Current Cancer Drug Targets PP2A in the Regulation of Cell Motility and Invasion
Current Protein & Peptide Science Systematic Analysis of Large Screening Sets in Drug Discovery
Current Drug Discovery Technologies Evolution of Resistance to Cancer Therapy
Current Pharmaceutical Design Maximizing Baculovirus-Mediated Foreign Proteins Expression in Mammalian Cells
Current Gene Therapy Current Dendrimer Applications in Cancer Diagnosis and Therapy
Current Topics in Medicinal Chemistry Impact of Human Immune Deficiency Virus Infection on Hepatitis C Virus Infection and Replication
Current HIV Research Oxidative-Nitrosative Stress In Hypertension
Current Vascular Pharmacology Anti-cancer Drug Delivery Using Metal Organic Frameworks (MOFs)
Current Medicinal Chemistry Bioactive Compounds in Some Culinary Aromatic Herbs and Their Effects on Human Health
Mini-Reviews in Medicinal Chemistry Corrosion Protection Performance via Nano-Coatings Technologies
Recent Patents on Materials Science